[{"address1": "1111 Kane Concourse", "address2": "Suite 301", "city": "Bay Harbor Islands", "state": "FL", "zip": "33154", "country": "United States", "phone": "781 652 4500", "website": "https://www.avenuetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.", "fullTimeEmployees": 3, "companyOfficers": [{"maxAge": 1, "name": "Dr. Alexandra  MacLean M.D.", "age": 56, "title": "CEO & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 413200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Jin", "age": 33, "title": "Interim CFO, COO & Corporate Secretary", "yearBorn": 1990, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lindsay Allan Rosenwald", "age": 68, "title": "Executive Director", "yearBorn": 1955, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott A. Reines M.D., Ph.D.", "age": 76, "title": "Interim Chief Medical Officer", "yearBorn": 1947, "fiscalYear": 2023, "totalPay": 69120, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.13, "open": 2.12, "dayLow": 2.12, "dayHigh": 2.2599, "regularMarketPreviousClose": 2.13, "regularMarketOpen": 2.12, "regularMarketDayLow": 2.12, "regularMarketDayHigh": 2.2599, "beta": -0.175, "trailingPE": 0.056563497, "forwardPE": -0.67515916, "volume": 54425, "regularMarketVolume": 54425, "averageVolume": 45274, "averageVolume10days": 26760, "averageDailyVolume10Day": 26760, "marketCap": 3034483, "fiftyTwoWeekLow": 1.89, "fiftyTwoWeekHigh": 45.0, "fiftyDayAverage": 2.51992, "twoHundredDayAverage": 6.53908, "currency": "USD", "enterpriseValue": -2821525, "floatShares": 1286403, "sharesOutstanding": 1431360, "sharesShort": 31536, "sharesShortPriorMonth": 36647, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.022, "heldPercentInsiders": 0.13163, "heldPercentInstitutions": 0.08129, "shortRatio": 1.14, "shortPercentOfFloat": 0.022, "impliedSharesOutstanding": 1431360, "bookValue": 4.004, "priceToBook": 0.5294705, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -14676000, "trailingEps": 37.48, "forwardEps": -3.14, "lastSplitFactor": "1:75", "lastSplitDate": 1714089600, "52WeekChange": -0.9527684, "SandP52WeekChange": 0.3593408, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ATXI", "underlyingSymbol": "ATXI", "shortName": "Avenue Therapeutics, Inc.", "longName": "Avenue Therapeutics, Inc.", "firstTradeDateEpochUtc": 1498570200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ab3c15b5-e280-3b5c-b842-8e87c6276492", "messageBoardId": "finmb_310815442", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.12, "targetHighPrice": 12.0, "targetLowPrice": 12.0, "targetMeanPrice": 12.0, "targetMedianPrice": 12.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 4919000, "totalCashPerShare": 3.437, "quickRatio": 4.237, "currentRatio": 4.296, "returnOnAssets": -2.01345, "freeCashflow": -13072750, "operatingCashflow": -8586000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-17"}]